Dysplasia Clinical Trials

178 recruitingLast updated: June 18, 2026

There are 178 actively recruiting dysplasia clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Chicago, Illinois, United States, Philadelphia, Pennsylvania, United States, Toronto, Ontario, Canada. Updated daily from ClinicalTrials.gov.


Dysplasia Trials at a Glance

178 actively recruiting trials for dysplasia are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 56 trials, with the heaviest enrollment activity in Chicago, Philadelphia, and Toronto. Lead sponsors running dysplasia studies include Mayo Clinic, Masonic Cancer Center, University of Minnesota, and Children's Hospital of Philadelphia.

Browse dysplasia trials by phase

Treatments under study

About Dysplasia Clinical Trials

Looking for clinical trials for Dysplasia? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dysplasia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dysplasia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 178 trials

Recruiting
Not Applicable

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

Pulmonary HypertensionBronchopulmonary Dysplasia
University of Alabama at Birmingham39 enrolled2 locationsNCT06373289
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 2

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled221 locationsNCT05554406
Recruiting

Early Detection of Advanced Adenomas and Colorectal Cancer

Colorectal, CancerColorectal NeoplasmsColorectal Adenocarcinoma+15 more
City of Hope Medical Center2,000 enrolled6 locationsNCT06342440
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled347 locationsNCT05564390
Recruiting
Not Applicable

Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.

Facial asymmetryOral Squamous Cell CarcinomaMucormycosis+3 more
Tishreen University30 enrolled1 locationNCT07654647
Recruiting
Phase 4

Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants

Bronchopulmonary Dysplasia (BPD)
Aristotle University Of Thessaloniki74 enrolled1 locationNCT07652684
Recruiting
Phase 2

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Intraventricular hemorrhageChronic lung disease of prematurityBronchopulmonary Dysplasia+1 more
OHB Neonatology Ltd.338 enrolled72 locationsNCT03253263
Recruiting
Not Applicable

EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))

Rheumatoid ArthritisOsteoarthritisTraumatic Arthritis+3 more
DePuy Orthopaedics118 enrolled5 locationsNCT06631638
Recruiting

Lung Ultrasound Score for Early Prediction of Bronchopulmonary Dysplasia in Preterm Newborns

Bronchopulmonary Dysplasia
Azienda USL Reggio Emilia - IRCCS40 enrolled4 locationsNCT07633184
Recruiting
Phase 1

Pharmacokinetics and Placental Transfer of Caffeine

Apnea of PrematurityPremature BirthBronchopulmonary Dysplasia+2 more
Indiana University30 enrolled1 locationNCT07570121
Recruiting
Phase 2Phase 3

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

Bronchopulmonary Dysplasia
Airway Therapeutics, Inc.366 enrolled50 locationsNCT06897839
Recruiting
Phase 1Phase 2

PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia

Critical IllnessBronchopulmonary Dysplasia (BPD)Premature Births
Duke University28 enrolled5 locationsNCT07101640
Recruiting

Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease

Bronchopulmonary Dysplasia
Boston Children's Hospital50 enrolled1 locationNCT05285345
Recruiting
Not Applicable

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

ThrombocytopeniaImmune ThrombocytopeniaMyelodysplasia
University Hospital, Bordeaux225 enrolled1 locationNCT04800458
Recruiting
Phase 1Phase 2

Safety and Efficacy of PTH-IA

Jansen's Metaphyseal Chondrodysplasia
National Institute of Dental and Craniofacial Research (NIDCR)12 enrolled1 locationNCT07541209
Recruiting
Not Applicable

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

Esophageal AdenocarcinomaBarrett EsophagusBarretts Esophagus With Dysplasia+1 more
Mayo Clinic450 enrolled5 locationsNCT06071845
Recruiting
Not Applicable

Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy

Arrhythmogenic Right Ventricular Dysplasia
University Hospital, Toulouse80 enrolled1 locationNCT05209776
Recruiting

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia ossificans progressiva
Ipsen100 enrolled5 locationsNCT06089616
Recruiting

Safety and efficacy of autologous fat grafting to reduce the risk of oesophageal stricture formation after endoscopic resection

Oesophageal dysplasia
St Vincent's Public Hospital Melbourne10 enrolled1 locationACTRN12626000631303